Obviously, the FDA would want to be certain that the benefit for using Vioxx in hemophilic arthropathy outweighed the attendant risk before allowing Vioxx (rofecoxib) to be reintroduced to the marketplace.
Vioxx, Once Vilified Like Thalidomide, May Also Return To The Market
